

**THE INDISPENSIBLE MISSION OF miRNA IN HUMAN DISORDERS**

Pramod Singh Khatri

PhD Scholar, Department of Pediatrics, AIIMS Hospital, India-110029

ABSTRACT

MicroRNAs (miRNAs) are short RNA molecule which tie to target miRNAs, bringing about translational constraint and gene silencing and are discovered in all eukaryotic cells. Roughly 2200 miRNA genes have been accounted for to exist in the mammalian genome, from which over 1000 have places with the human genome. Numerous major cell abilities, for example expansion, separation, development, and breakdown are known to be controlled by miRNAs. Closeness to different genes in the genome and their areas in introns of coding genes, noncoding genes and exons have been accounted for to have a major impact on the level of gene understandings in eukaryotic cells. MiRNAs are overall preserved in eukaryotic framework and are accepted to be a vital and evolutionary antiquated part of gene regulatory systems. Hence, recently miRNAs have been mulled over as a presumable candidate for inclusion in generally biologic procedures and have been associated in numerous human disorders.

KEYWORDS: MicroRNA, miRNA, Human Genome

INTRODUCTION:

Ever since the first draft of human genome was dispersed in February 2001, numerous new discoveries have been made which have illuminated the unpredictability of the human genome and thusly the human proteome. In the previous decade, provision of genomics and proteomics innovations for unanticipated identification of infections have exhibited that numerous sorts of ailments might be diagnosed at an early stage which might be helpful in start of treatment procedure at a prior time indicate in the center. There have been various applications of proteomics innovations for unanticipated discovery of ovarian malignancy^(1, 2, 3), prostate tumor⁽⁴⁾, lymphatic vascular framework⁽⁵⁾ and medication affected cardiovascular toxicities⁽⁶⁾. Different genomics and proteomics advances have been utilized in an assortment of different illnesses in the preceding decade^(7, 8).

As a consequence of human genome studies and the revelation of less than 25,000 genes in the human genome, a movement has happened in the center of examination from mRNAs to noncoding RNAs as a major controller of human genome. The vicinity of noncoding RNAs and its part in numerous human illnesses make these molecules vital arbiters which must be comprehended in medicinal research. I will represent this review article in a more extensive manner to incorporate numerous different sorts of illnesses that are currently known to happen in human.

In promptly 90's, it was identified that two minor RNAs (in place of a protein) were the result of lin-4, a gene regulating the timing of larval advancement of *Caenorhabditis elegans* (*C. elegans*)⁽¹⁰⁾. Later studies

revealed that the longer RNA (70 nucleotides) was the originator of the shorter RNA (22 nucleotides) which is currently regarded as a part of the class of microRNAs (miRNA) genes⁽¹¹⁾. By focusing on particular mRNAs for degradation or translational constraint, microRNAs (miRNAs), a unique class of endogenous, non-coding RNAs (ncRNAs) assumes a vital part in regulating gene understanding⁽¹²⁾. Initially it was believed that lin-4 gene expression was limited to *C. elegans*, because of absence of homology with different species. How-ever, in the year 2000 the miRNA gene (let-7) (result of lin-4 gene precursor) was revealed to target lin-41(a protein coding gene) in numerous species⁽¹³⁾. Since then extensive measures of microRNAs have been distinguished in vertebrates⁽¹⁴⁾. Parts of ncRNAs incorporate microRNAs (miRNAs) and small nucleolar RNAs (snoRNAs) that are known to have overall saved abilities in different species. The protection of ncRNAs' exercises in arbitrating the coupling of RNA-enzyme to target RNA edifices comes about because of their particular hybridization to other nucleic acids in the cell and their directing ability of diverse cellular targets. Such particular functions are thinking to limit succession covariation and tendency to advancement⁽¹⁶⁾. As the human genome and its capacities are quickly being deciphered, the functions of miRNAs are coming to be more apparent in particular cell functions. For instance, miRNAs and an imposing set of ncRNAs together with: Air, H19, lpw, NTT, Tsix and Xist in warm blooded animals (reputed to be "gene regulators") have been proposed to have distinctive functions going from engraving to inactivation of X-chromosome in vertebra⁽¹⁷⁾.




Figure 1: The biosynthesis path-way of miRNAs

The biogenesis of miRNAs (Figure 1) includes numerous steps and particular cell machinery⁽¹⁸⁾. miRNAs are determined as short distorted repeats having a twofold stranded RNA (dsRNA) stem circle in the ballpark of 70 bp long and are discovered in both introns and intergenic bunches in the genome⁽¹⁸⁾. RNA polymerase II is accountable for the amalgamation of the introns and exons of both protein-coding and non-coding transcripts from where miRNAs are inferred⁽¹⁹⁾. In the core nucleus, miRNAs are translated as essential pri-miRNA transcripts then afterward are transformed to structure the antecedent pre-miRNA stem circle structure before moving into the cytoplasm [where they are divided by the Dicer RNAase III endonuclease and produce adult miRNA (21-23 nucleotides)]⁽²⁰⁾.

MICRORNAS IN THE INTERIOR OF HUMAN GENOME:

Numerous major cell functions, for example growth, separation, development, and breakdown are directed by miRNAs and pretty nearly 2200 miRNA genes have been accounted for to exist in the vertebra genome⁽²¹⁾. One third of the human genome is evaluated to be directed by miRNAs⁽²²⁾. The exact mechanism included in the miRNA interpretation is not known however vicinity to different genes in the genome and their areas in introns of

coding genes, noncoding genes and exons are accounted for to impact their interpretation⁽²³⁾. In the genome, miRNAs are composed in bunches and portion the same transcriptional administrative units and are individually communicated in the event that they have their own particular promoters^(24, 25). It is evaluated that in the ballpark of 50% of miRNAs communicated in the genome are deciphered from non-protein-coding genes and the remaining miRNAs are encoded in the introns of coding genes⁽²¹⁾.

In higher eukaryotic organic entities, nearly the whole genome (97%) is deciphered as non-coding RNA (ncRNA) which comprise of rRNA, tRNA, introns, 5' and 3' untranslated locales, transposable components, intergenic regions, and microRNAs^(12, 26). As of late, it has been prescribed that mammalian miRNAs are determined from DNA rehashes and transposons⁽²⁷⁾. Such information have prime the scientific group to reevaluate the useful part of transposons, exclusively since it creates the impression that the particular successions of transposons can assume a major part in the developmental methods and epigenetic varieties^(28, 29). Besides, it has been recently exhibited that miRNAs might be inferred from transformed pseudogenes⁽³⁰⁾, which were once accepted to have no cell capacities (Figure 2).




Figure 2: Coding region and non-coding DNA region in human genome

Latest sequence analysis of the human genome exhibits that the protein coding genes may be as flat as 25,000⁽³¹⁾. Despite the fact that the precise number of the protein coding genes in the human genome is not known, the 25,000 figure is no less than 3-4 times more level than the figure had confidence in late 1980's. What these new information uncover is that a huge portion of the human genome comprises of non-coding protein genes. Further sequence investigations show that the Open Reading Frames (ORFs) contain less than 2%, tedious sequence around 46%^(32, 33) and noncoding parts of protein-coding genes (introns, 5' and 3'-UTRs) an expected 25–27%⁽³⁴⁾ of the 3.2 billion bases in the human genome.

MICRORNAS PRESENCE IN OTHER GENOMES:

Notwithstanding their major vicinity in the human genome, microRNAs have been indicated to be included in regulation of genes in higher eukaryotes⁽³⁵⁾. The fast development of research in the field of miRNAs is watched in the amount of entries in the miRNA registry (form 1), with just 218 entries in 2002 and in the vicinity of 6500 entries in 2008 (variant 11)^(36, 37). The sequence investigates of genomes in eukaryotes demonstrate that basic unicellular living beings, spineless creatures and well evolved creatures have 10-40%, 70-90% and 98% of their genomes made out of noncoding DNA region, separately⁽³⁴⁾. The cell capabilities of miRNAs seem to differ in eukaryotes, incorporating regulation of leaf and bloom growth in plants⁽³⁸⁾ and adjustment of separation of hematopoietic cell in warm blooded animals⁽³⁹⁾. The way that numerous micro RNAs' sequences are saved around distantly identified living beings demonstrates that miRNAs are included in essential cell forms⁽⁴⁰⁾.

MICRORNAS FUNCTION IN HUMAN DISEASES:

MicroRNAs have been exhibited to assume a major part in an extensive variety of developmental procedures incorporating breakdown, cell burgeoning, apoptosis, developmental timing, and neuronal cell destiny^(15, 41 -44). Other regulatory function might be neuronal gene

illustration⁽⁴⁵⁾, brain morphogenesis⁽⁴⁶⁾, muscle separation⁽⁴⁷⁾, and stem cell division⁽⁴⁸⁾. the function of miRNAs as a major source in the advancement of cancer disease is still a lot unappreciated⁽⁴⁹⁾. Yet adjusted examples of miRNAs in cells have been demonstrated to be answerable for change that reason cell to settle on a choice to turn malignant⁽⁵⁰⁾. microRNAs are currently distinguished to assume a imperative function in the regulation of certain processes identified with progress in all eukaryotes and in view of their potential function as executors regulating cell development and separation, they have been proposed to be exceptional appointees for cancer treatment^(51, 52). MicroRNAs' lacks or abundances have been joined to various other clinically imperative ailments extending from myocardial dead tissue to immune system infection. Single point transformations in miRNA or its target or epigenetic hushing of miRNA translation units is an instrument by which the capacities of miRNA in cell are influenced⁽⁵³⁾. Extraordinary findings and fast advancement in the previous not many years on miRNAs give the trust that miRNAs will in the close future have an extraordinary potential in the finding and medicine of numerous infections. In the accompanying pages, the function of miRNAs as significant new administrative molecule in diverse human maladies will be surveyed⁽⁵⁴⁾.

MICRORNAS ROLE IN CANCER MALIGNANCY:

It is currently generally reported that up-regulation or down-regulation of miRNAs happens in different human cancer malignancies (9). Over-expressed miRNAs might play a role as both oncogenes (through down-regulation of tumor-silencer genes) or controller of cell methods, for example cell separation or apoptosis (55, 56).unique miRNA outflow profiling have been showed for numerous sorts of tumor. A record of such profiles for regenerative diseases (breast, ovary, and endometrioid adeno carcinoma) and colon, hematological malignancies (Aml, All, Cml, Cll), throat, gastrointestinal, lung, bladder, and thyroid tumors are demonstrated in tables 1⁽⁹⁾. It has been expected that microRNAs will have an extraordinary

potential to be utilized as a part of judgment and medicine of growth in the close future (Tables1-2

Table 1: miRNA function in Cancer Malignancy

Cancer Type	miRNA	Up/Down Regulation
AML	Has -miR -191,199a ,miR155	Up regulation
CML	miR -17-5p ,miR-173p ,miR -18a ,miR-19b-1, miR-20a ,and miR-92a-1	up regulation
Ovary	miR-200a ,miR-200c ,miR-141,miR-199a	up regulation
	miR-140 ,miR145 ,and miR 125bl	down regulation
endometrioid adenocarcinoma	miR-205 ,miR-155 ,miR 200a ,200b,200c	up regulation
	miR-193a, 193b	down regulation
breast	miR-21 ,miR-155 ,,miR-23 ,miR-191	up regulation
	miR-205 ,miR-145 ,miR-10b ,miR-125b	down regulation
colon	miR-let7g ,miR-21 ,miR-20a ,miR17-19 family ,miR31 ,miR135 miR-181b and miR 200c	up regulation
	miR 34 ,miR -let7 ,miR 143 ,miR145 ,miR-133b,miR-126	down regulation
CLL	miR-21 ,miR 150 ,miR-155	up regulation
	miR-15a ,miR16 ,miR 29 ,miR143 ,miR45 ,miR-30d miR-let 7a ,miR -181a	down regulation

Endothelial cells are known to assume a major part in the angiogenesis methodology. In latest studies ^(57 -59) the miRNA articulation example (known for its tissue and cell sort specificity) in endothelial cells has been exhibited to incorporate let-7b, miR-16, miR-21, miR-23a, miR-29, miR-100, miR-221, and miR-222. The regulation of miRNAs throughout patho-physiological courses of action has been prescribed to help uncovering the function of miRNAs in vascular units. For instance in two latest reports ^(60, 61), the regulation of miRNAs in vascular cells according to serum and hypoxia have been studied. In one study ⁽⁶⁰⁾ the pro- angiogenic miR-130a is communicated at Low levels in peaceful HUVEC and is up-directed according to foetal bovine serum. In a different study ⁽⁶¹⁾ hypoxia was demonstrated to prompt miR-210 interpretation in endothelial units. The overexpression of miR-210 was accounted for to be connected with the upgraded arrangement of capillary like structures in as much as restraint of miR-210 expression was joined to

diminished tube development and movement ⁽⁶²⁾. miR-221 and miR-222 are around the remarkably communicated miRNAs in HUVEC that display against angiogenic impacts ⁽⁵⁹⁾. Comparable perceptions were accounted for ⁽⁵⁷⁾ for the opposition to angiogenic capacity of miR-221 and miR-222 in endothelial cells. This study additionally indicated that the overexpression of miR-221 and miR-222 likewise in a roundabout way lessens the articulation of the endothelial Nitric Oxide Synthase (eNOS) ⁽⁵⁷⁾.

Nitric oxide (No) is a significant Molecule in managing endothelial cell development ⁽⁶³⁾, migration ⁽⁶⁴⁾, vascular redesigning ⁽⁶⁵⁾, and angio-genesis ⁽⁶⁶⁾ and its hindered bioavailability is the explanation for infections incorporating: atherosclerosis and ischemic cardiomyopathy ⁽⁶⁷⁾. Recently it was exhibited that eNOS additionally assumes a major part in the preparation and practical action of stem cells ^(68 -70); therefore, outlining miRNAs to target eNOS is thought to direct vasculogenesis ⁽⁶²⁾.

Table -2 miRNA Function in cancer disorders

Cancer Type	miRNA	Up /Down Regulation
lung	has -miR-21 ,has-miR-205 ,mir-17-92	up regulation
	has -miR-126 ,miR -let-7a ,let -7f-1	down regulation
Esohagous	miR -19 ,miR-192 ,miR-200c	up regulation
	miR-203	down regulation
Thyroid		
AC	miR-30d ,miR-125b ,miR-26a ,miR-30a-5p	down regulation
PC	miR -146 b, miR-221 ,miR-222 ,miR-181b	up regulation
bladder	miR-223 ,,miR26b ,miR221 ,miR-103-1 ,miR-23-b	up regulation
	miR-203 ,miR17-5p ,miR-23 ,miR-205	
	miR-29c ,miR-26a ,miR-30c ,miR-30e-5p	down regulation
gastro-intestinal	miR -15b ,miR-16	down regulation
	miR -106b-25	up regulation

MICRORNAS ROLE IN CARDIOVASCULAR DISEASE:

The homoeostasis of the vascular framework relies on the usefulness of endothelial units and facilitated regulation of angio-genesis, vasculogenesis, and vessel relapse. Small is pondered the about regulatory machinery at the gene outflow level throughout neovascularization and vascular renovating ⁽⁶²⁾. however, the finding of microRNAs in recent period has made it clear that these RNA molecule have a vital capacity in regulation of heart function ⁽⁷¹⁾ and mammalian cardiovascular framework all in all ⁽⁷²⁾.the miRNA expression levels have been interfaced to deregulation of developmental methods and illness states, for example heart hypertrophy and failure. Numerous miRNAs are communicated in a tissue-cell –specific way ⁽⁷³⁾ and in adult cardiovascular tissue, miR-1, miR-16, miR-27b, miR-30d, miR-126, miR-133, miR-143, and the let-7 family are plentifully communicated ⁽⁷⁴⁾. Studies have demonstrated that three miRNAs (miR-1, miR-133, and miR-208) are exceptionally communicated in the heart ^(23, 75) and are vital controllers of heart development and myocyte separation ^(72, 76 -78). Recently, deregulated expression of miR-1 and miR-133 were accounted for in human failure ^(71, 79, 80).

CARDIAC FAILURE:

Extreme cardiovascular rebuilding with inconvenient conclusions can come about because of unsettling influences in the physiological stimuli to the heart ⁽⁸¹⁾. One of the major reactions of the heart to such stimuli is a broad tissue redesigning regarded as obsessive hypertrophic development. Despite the fact that the exact mechanism included in cardiovascular biotic capacities are not known, an expanding number of studies infer that miRNAs are paramount controllers of cardiovascular development, multiplication, cell

separation, and apoptosis. Cardiac hypertrophy in people is a major determinant of mortality and dreariness in cardiovascular illnesses. Since miRNAs are vital controllers for the separation and development of heart cells, they are guessed to have an imperative part in heart hypertrophy and heart washout ⁽⁸²⁾. Indeed, several latest reports have discovered abnormal declaration of miRNAs in unhealthy hearts and vessels. miR-23a, miR-23b, miR-24, miR-195, miR-199a, and miR-214 were upregulated throughout cardiovascular hypertrophy (Table 3) also their over-expression in cardiomyocytes in vitro made an impelling of hypertrophic development. Interestingly, miR-24, miR-125b, miR-195, miR-199a, and miR-214 were comparably upregulated in the tissue of patients with end stage fizzling human hearts ⁽⁷⁴⁾.

Heart arrhythmias are still acknowledged a genuine health issue due to their sudden, eccentric and conceivably lethal nature. In human hearts with coronary illness and the rodent model of myocardial localized necrosis, it has been indicated that the muscle-specific miRNA (miR-1) is upregulated in ischemic heart tissue ⁽⁶¹⁾. Moreover, the outcomes of this study show that the infusion of full grown miR-1 fuels arrhythmogenesis, although hindrance of mRr-1 by an antisense inhibitor stifles arrhythmias. The point when the genes for the ion channels GIA1 and KCNJ2 were hushed, these proteins were demonstrated to be critical in interceding the miR-1 affected arrhythmogenic impact ⁽⁶¹⁾. The examination into the function of miRNAs as a novel class of gene controllers in cardiovascular ailment is another outskirts for examination and it is trusted that the following decade will carry a more stupendous understanding to their capacities in cardiovascular biology ⁽⁸²⁾.

Table 3: miRNA Function in cancer disorders

Disease type	miRNA	Up /Down Regulation
Alzheimer	miR-9 ,miR-128b ,miR-125b	up regulation
Down syndrome	miR-99a ,let-7c ,miR-125b-2 ,miR-155 ,miR-802	up regulation
Rheumatic arthritis	miR-155 ,miR-146	up regulation
Systemic lupus erythematous	miR-189 ,miR-61 ,miR-78 ,,miR-21 ,miR-142-3p	up regulation
	miR342 ,miR-299 -3p ,miR-198 ,miR-298	
	miR-196a ,miR-17-5p ,miR-409-3p ,miR -383	down regulation
	miR-112 ,miR-184	
Psoriasis	miR-203	up regulation
Cardiac hypertrophy	miR-23a ,miR-23b ,,miR-24 ,miR-195 ,miR-199a	up regulation

MICRORNAS FUNCTION IN INFLAMMATORY DISEASE:

Inflammation is a key part of host safeguard framework and a major reaction to infection and damage, which is accepted to give to various intense and ceaseless diseases (83, 84). Recently various studies have explored the function of miRNAs in vascular inflammation and leukocyte enactment and their invasion into the vascular divider. Actually, a latest study (85) gives the first confirmation that miRNAs control vascular infection. In this study, miR-126 was exhibited to restrain the representation of vascular cell adhesion molecule 1 (VCAM-1), which is solicited to intervene leukocyte adherence to endothelial units. In macrophages, miR-155 has been demonstrated to be incited by cytokines, for example TNFα and IFN-β (86, 87) and donate to physiological granulocyte/ monocyte development throughout aggravation (88). Moreover, miR-155 is accounted for to be needed for B and T lymphocyte and dendritic cell function (89,90). At the gene level, the transcription factor Pu.1 has been distinguished as an immediate focus of mir-155 in B cells (62, 90).

An additional study (91) has exhibited that miR-181 is included in regulation of hematopoietic lineage separation and numerous miRNAs have been accounted for to direct B-cell separation, incorporating the miR-17-92 bunch and miR-150 (92 -94). Throughout monocyte separation, the translation of miR-424 has been demonstrated to build and manage the interpretation of the translation component NFI-A included in monocyte/ macro-phage separation (95). Besides, miR-146 is discovered to be prompted in macrophages by a few microbial parts and proinflammatory cytokines (96). At last, the myeloid-particular miR-223 is accounted for to be included in regulation of granulocyte separation and actuation throughout irritation (62, 97). The part of miRNAs in regulation of each major cell type critical in tweak of the invulnerable framework shows that they might be possibly utilized as a part of immune therapies.

MICRORNAS ROLE IN NEURODEVELOPMENTAL AILMENT:

MicroRNAs are greatly linked in human and other mammalian brains with respect to different organs (98 -100). The outcomes of high-throughput number of miRNAs communicated in human cerebrum ought to be over 1000, despite the fact that as of now this number stands at something like 550 in all people (101). The articulation of miRNAs in brain changes throughout brain development. Accordingly, a few miRNAs are communicated all the more inexhaustibly throughout unanticipated improvement in the mammalian cerebrum, and nearly are communicated less throughout later growth phase (102, 103). The progressions in miRNA expression levels in cerebrum throughout development might stand for biochemical signs for cell destiny determination, apoptosis or cell division programming (104). Studies (105) have demonstrated that a few miRNAs are differentially communicated in neuronal nuclei, or diverse cell populaces in brain (106).because miRNAs are known to be alterably controlled in neurogenesis and brain growth (107, 108), it is accepted that miRNAs are additionally included in neural development and assume a paramount part in intervening neuronal versatility. One of the major normal trait joining a number of the neurodevelopmental disarranges [e.g. intellectual inability, a mental imbalance, Attention Deficit Hyperactivity Disorder (ADHD) and epilepsy] is that illness onset happens throughout times of development and that miRNAs contribute fundamentally to the pathogenesis of neurodevelopmental disorders at the molecular level (110). Concerning the part of non-coding RNAs (particularly miRNAs) in human cerebrum, it is guessed that these particles may assist the era of multifaceted complexity needed for brain function from more or less 25, 000 human protein-coding genes (106, 111, 112).

A. Fragile X syndrome:

Fragile X Syndrome (FXS) is the first hereditary disorder connected to the miRNA pathway^(113 -115). The clinical appearances of FXS incorporate: learning disabilities, extreme cognitive or erudite disabilities and deferrals in speech and dialect development⁽¹¹⁶⁾. The fragile X mental retardation 1 (FMR1) gene is connected with a huge precarious CGG trinucleotide repeat expansion inside the gene's 5' untranslated region (5'-UTR)⁽¹¹⁷⁻¹¹⁹⁾. The useful FMR1 gene product, Fragile X Mental Retardation Protein (FMRP), fits in with a little and greatly saved RNA-binding protein family^(120 -124) and function as a silencer of target mRNA translation through binding of non-coding RNA structures inside the UTRs of target mRNAs^(110, 125 -128). Recombinant human FMRP has been indicated to have the capacity to fill in as an acceptor for Dicer-determined miRNAs, and altogether, endogenous miRNAs are discovered connected with FMRP in both flies and vertebrates⁽¹¹³⁻¹¹⁵⁾. This connection is dared to direct interpretation of target mRNAs and exhibits the contribution of miRNA machinery in instigating the hereditary Fragile X syndrome.

B. Rett syndrome:

The X-linked dominant Rett syndrome (RTT)⁽¹²⁹⁾ is a progressive neurodevelopmental jumble and a standout amongst the most well-known explanations for mental impediment and includes a de novo transformation in MeCP2 gene known to make distortions in the DNA methyl-CpG-binding protein, MeCP2^(110, 130). Interestingly, it has been exhibited that in postnatally cultivated rat neurons, miR-132 unswervingly suppresses expression of MeCP2. This perception may show that the function of miRNA is critical in regulation of MeCP2 as a mechanism by which standard neuronal development and synaptic maturation in the postnatal brain is maintained⁽¹³¹⁾. The function of MeCP2 in immediate regulation of the expression of miRNA genes and the role of miRNAs in the pathogenesis of RTT is even now being dead set.

C. Down syndrome:

Down Syndrome (DS) comes about because of triplication of all or part of human chromosome 21 and influences 1 in 700 babies and is showed with variable phenotypes, for example congenital heart deformities, craniofacial anomalies cognitive debilitation⁽¹³²⁾. Recently, bioinformatics examinations of chromosome 21 have uncovered that five miRNAs (miR-99a, let-7c, miR-125b-2, miR-155 and miR-802) are encoded on this chromosome. Interestingly, every one of the five miRNAs have been indicated to be overexpressed in fetal cerebrum and heart tissues from DS patient inferring a role in the cognitive and heart defects observed in DS (table 3)^(110, 133). In general, people with DS show lower level blood pressure and lower angiotensin II type 1 receptor (AGTR1) protein levels than those without DS. Latest study⁽¹³⁴⁾ has reported that miR-155 down regulates AGTR1, a human gene connected

with hypertension; hence furnishing potential confirmation that miRNAs contribute to the DS phenotypes.

D. Alzheimer's disease:

Dysregulated miRNA interpretation has been accounted for in the cerebrum of Alzheimer patients⁽¹³⁵⁾. Particular miRNAs have been exhibited to be joined to the pathogenesis of Alzheimer's disease (AD). For instance, misfortune of miR-29 cluster has been demonstrated to be connected with expanded (beta-amyloid antecedent protein-changing enzyme) BACE1/ beta secretase expression in sporadic AD patients⁽¹³⁶⁾. Besides, miR-298 and miR-328 have been recognized to straightforwardly communicate with the 3'-UTR of the BACE1 transcript that is included in b-amyloid preparation⁽¹³⁷⁾. miR-17-5p and miR-106b has been showed to control the expression of Amyloid Precursor Protein (APP) raising the probability of a role for these micro RNAs throughout AD improvement^(138, 139).

DNA arrays were utilized to examine and assess the expression of a subset of 12 miRNAs in the AD hippocampus in examination with non-unbalanced controls and fetal brain^(140, 141). The effects of the articulation profiling demonstrated that miR-9, miR-128a and miR-125b are hoisted in AD hippocampus (Table 3)⁽¹⁴⁰⁾. In an additional study⁽¹⁴¹⁾, refined human fetal brain inferred primary neural (HN) cells were indicated to be incited for creation of Reactive Oxygen Species (ROS) in vicinity of metal salts, for example aluminum and iron sulfates. Synchronously, these cell were exhibited to have increased articulation of miR-9, miR-128 and to a lesser degree miR-125b, prescribing that ROSs impact AD brain through pathways explicitly interceded by miRNAs. Further illuminations of the function of miRNAs being developed of AD stay to be illustrated in near future.

E. Huntington's Disease:

Huntington's disease (HD) is a neurodegenerative ailment came about because of CAG expansion in the gene encoding the protein huntingtin (Htt). The signs of HD incorporate cognitive imperfections and motor control impairment which expedite neuronal dysfunction described by ongoing loss of cortical and striatal neurons⁽¹⁴²⁾. How this procedure is directed is not unequivocally known; however numerous potential miRNA targets have been anticipated in the brains of HD sufferers. In the cortex of the rodent model of HD (R6/2), from seven target miRNAs which were discovered to be expressed after 40 cycles of qPCR, four microRNAs (miR-29a, miR-124a, miR-132 and miR-135b) showed huge decrease in expression⁽¹⁴³⁾.

Interestingly, around the dysregulated miRNAs discovered in the cortex of the rodent model of HD, miR-124a and miR-132 are recognized for their significant neuronal specific action. These effects demonstrate that extensive and critical dysregulation of target miRNAs happens in the brains of R6/2 animals. In tissue samples

from human unaffected individuals ('WT') and HD-sufferers ('HD'), target miRNAs, miR-29a, miR-124a, miR-132 and miR-330 have been spotted however not demonstrated to be altogether over or under expression at any particular pathologic state in HD⁽¹⁴³⁾.

A few Researchers have prescribed that the outcomes from rodent and human specimens can't be thought about on the grounds that they are taken from diverse regions and are from diverse species. In spite of the fact that no experimentally accepted target mRNAs have been accounted for the miRNAs in the brain of HD patients, transcriptional dysregulation of miRNAs in human HD cortex has been indicated and further studies are obligatory to make the collaboration between miRNAs and HD in the clinic.

F. Schizophrenia:

Schizophrenia is a neuropsychiatric ailment that more or less influences 1 in 100 people in a general community⁽¹⁴⁴⁾. Schizophrenia is a genetic jumble^(145, 146) and Brain-Derived Neurotrophic Factor (BDNF) has been indicated to assume a vital part in the regulation of the advancement and synaptic support of a mixed bag of neurons in the CNS incorporating GABA and glutamatergic neurons^(147, 148). Besides, BDNF might direct type 3 dopamine receptor (DRD3) expression throughout brain growth⁽¹⁴⁹⁻¹⁵¹⁾.

Latest bioinformatics examinations have shown that two recently depicted miRNAs, hsa-miR-1 and hsa-miR-206, may focus on the 30-UTR of BDNF⁽¹⁵²⁾. This prescription gives assurance to the speculation that miRNA could direct BDNF protein synthesis by meddling with BDNF mRNA interpretation throughout cerebrum development.

MICRORNAS FUNCTION IN AUTOIMMUNE DISEASE:

Outcomes from both cell culture and animal studies show that miRNAs have an imperative part in regulation of ordinary immune capability and counteractive action of auto-immunity. It is not clear what is the exact mechanism by which miRNA dysregulation could expedite pathogenesis in an immune system ailment. In the accompanying areas some conceivable functions for miRNAs in regulation of two of the most important immune system maladies [i.e. rheumatoid arthritis (RA)] and Systemic Lupus Erythematosus (SLE) will be explored⁽¹⁵³⁾.

A. Rheumatoid arthritis (RA):

In a latest study⁽¹⁵⁴⁾, an anomalous expression of miRNAs was accounted for in patients with RA. In particular, two microRNAs (miR-155 and miR-146) were discovered to be expressed at a fundamentally more elevated level in synovial tissues and synovial fibroblasts secluded from patients with RA, with respect to healthy controls (Table3). Remarkably, the levels of both these miRNAs were discovered fundamentally upregulated in

synovial fibroblasts from patients with RA taking after TNF/interleukin (IL)-1 β stimulation^(155, 156). Evidence from rodent 3'-UTR mutational studies has involved interaction between miRNAs and TNF transcripts^(157, 158). In the close future, the recognizable proof of candidate miRNAs that target genes concerned in rheumatic disorder may increase our molecular comprehension answer for rheumatic ailment. Besides, Inducible Costimulator (ICOS) was recently showed up for a focus of miR-101⁽¹⁵⁹⁾, and ICOS-lacking mice are demonstrated impervious to collagen prompted arthritis without any indications of joint tissue inflammation⁽¹⁵⁶⁾.

Pathogenesis of RA has been connected with the viral contaminations, for example Epstein Barr Virus (EBV), chronic Hepatitis C Virus (HCV), HIV and Kaposi's sarcoma associated herpes. Mixed bag of reports shows that infections can encode their own particular miRNAs and these viral-encoded miRNAs can control the articulation of viral transcripts and smother the host resistant reaction throughout infection. For instance, miR-UL112-1 communicated by the human cyto-megalovirus has been tested to target the major histocompatibility complex class 1-identified chain B. Additionally, miR-k12-11 encoded by the Kaposi's sarcoma-associated herpes infection, has been accounted for to down-regulate the expression of various comparative cell target mRNAs. Hence, it is conceivable that viral-encoded miRNAs by focusing on distinctive host proteins can affect provocative joint inflammation⁽¹⁵⁶⁾. Three studies have showed adjustment of miRNA declaration in RA patients related to controls^(154, 155,). In particular, expanded miR-155 and miR-146a articulation in RA synovial fibroblasts have been in correlation to those patients with Osteoarthritis (OA)⁽¹⁵⁵⁾.

B. Systemic Lupus Erythematosus (SLE):

SLE is a systemic inflammatory immune system malady with differing clinical appearances incorporating photosensitivity, joint pain, glomerulonephritis, and neurological sickness. In a latest microarray dissection of miRNA interpretations in SLE patients, seven miRNAs (miR-196a, miR-17-5p, miR-409-3p, miR-141, miR-383, miR-112, and miR-184) were discovered down regulated and nine miRNAs (miR-189, miR-61, miR-78, miR-21, miR-142-3p, miR-342, miR-299-3p, miR-198, and miR-298) upregulated contrasted with healthy controls (Table 3)⁽¹⁶⁰⁾. The miRNA profiling of kidney biopsies from lupus nephritis patients indicated sixty six differentially expressed miRNAs (36 upregulated and 30 down regulated) when contrasted with healthy controls⁽¹⁶¹⁾. Obviously, further studies are solicited to verify if the differential expression of these miRNA in SLE patients are reproducible⁽¹⁶²⁾.

MICRORNAS ROLE IN SKIN DISEASE:

The association of miRNAs in hair follicle morphogenesis, immune system and chronic inflammatory sicknesses influencing skin has been proposed⁽¹⁶³⁾. Dermal fibroblasts are essential cells included in the wound recuperating methodology⁽¹⁶⁴⁾. Dissection of the potential

association of miRNAs in controlling the transition to expansion has been performed and a bunch of 33 miRNAs were accounted for to be included in regulation of expression of target genes needed for the entrance of fibroblasts into the cell cycle and expansion⁽¹⁶⁵⁾. A latest survey has plot the potential criticalness of miRNAs' inclusion in wound angiogenesis and aberrant healing sequence in chronic wounds⁽¹⁶⁶⁾.

PSORIASIS:

Psoriasis is an incessant inflammatory skin ailment and hereditary and environmental elements are supposed to be included in pathogenesis of the malady. It is substantially acknowledged that psoriasis comes about because of weakened correspondences between the immune system and the structural cell of the skin⁽¹⁶⁷⁾. The psoriasis related miRNAs have been distinguished in the skin and miR-203 was discovered to be expressed more than 100-fold higher in skin contrasted with different organs (Table 3). Expression breakdowns of psoriasis-cohorted miRNAs (miR-203, miR-146a, miR-21, and miR-125b) in cells that exhibit in healthy and blasts, melanocytes, and leukocyte/ immune cell subsets) have been indicated to have a different representation design⁽¹⁶⁸⁾. Such studies exhibit that psoriasis-specific miRNA are included in the pathogenesis of psoriasis.

FUTURE PERSPECTIVE OF MIRNA:

A standout amongst the most energizing discoveries of human genome venture has been the finding of a major class of non-coding protein RNA molecules. The discoveries of human genome venture have exhibited that the DNA molecules a while ago regarded as "garbage DNA", is currently actively translated and code for miRNAs. Studies now provide evidence that miRNAs assume a crucial part in an assortment of developmental techniques and illness as assessed in the present article. miRNAs as an uncommon class of non-coding RNAs can post-transcriptionally regulate gene articulation in a negative way; hence, it is anticipated to have an incredible potential in identification and medicine of ailments in near future. For example, in last few years, a few procedures, for example miRNA silencing, antisense blocking and miRNA alteration have been recognized for potential helpful treatment of numerous sorts of cancer diseases. As the part of miRNAs are further cleared up and secured in every malady, we will likely see new method developed to address the analysis and medicine of major human infections. This new information seems to have a major role in the practice of personalized medication in the close future.

COMPETING INTERESTS:-

The authors declare that they have no competing interests

REFERENCES:

1. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, et al. Use of proteomic patterns in serum to identify ovarian cancer. *The Lancet* 2002;359(9306):572-577.
2. Ardekani AM, Lance A Liotta LA, Petricoin EF. Clinical potential of proteomics in the diagnosis of ovarian cancer. *Expert Rev Mol Diagn* 2002;2(4): 312-320.
3. Liotta LA, Petricoin EF, Ardekani AM, Hitt BA, ovarian cancer. *Gynecol Oncol* 2003;88(1 Pt 2): S25-28; discussion S37-42.
4. Petricoin III EF, Ornstein DK, Paweletz CP, Ardekani AM, Hackett PS, Hitt BA, et al. Serum proteomic patterns for detection of prostate cancer. *J Natl Cancer Inst* 2002;94(20):1576-1578.
5. Leak LV, Petricoin EF, Jones M, Paweletz CP, Ardekani AM, Fusaro VA, et al. Proteomic technologies to study disease of the lymphatic vascular system. *Ann NY Acad Sci* 2002;979:211-228.
6. Petricoin EF, Rajapaske V, Herman EH, Ardekani AM, Ross S, Johann D, et al. Toxicoproteomics: serum proteomic pattern diagnostics for early detection of drug induced cardiac toxicities and cardioprotection. *Toxicol Pathol* 2004;32(Suppl1):122-130.
7. Li X, Conklin L, Alex P. New serological biomarkers of inflammatory bowel disease. *World J Gastroenterol* 2008;14(33):5115-5124.
8. Kurian S, Grigoryev Y, Head S, Campbell D, Mondala T, Salomon DR. Applying genomics to organ transplantation medicine in both discovery and validation of biomarkers. *Int Immunopharmacol* 2007;7(14):1948-1960.
9. Moslemi Naeini M, Ardekani AM. Noncoding RNAs and Cancer. *Avicenna J Med Biotech* 2009; 1(2):55-70.
10. Lee RC, Feinbaum RL, Ambros V. The *C. elegans* heterochronic gene *lin-4* encodes small RNAs with antisense complementarity to *lin-14*. *Cell* 1993;75(5):843-854.
11. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. *Science* 2001;294(5543):853-858.
12. Sevignani C, Calin GA, Siracusa LD, Croce CM. Mammalian micro RNAs: a small world for finetuning gene expression. *Mamm Genome* 2006;17(3):189-202.
13. Pasquinelli AE, Reinhart BJ, Slack F, Martindale MQ, Kuroda MI, Maller B, et al. Conservation of the sequence and temporal expression of *let-7* heterochronic regulatory RNA. *Nature* 2000;408:86-89.
14. Zhang C. MicroRNAs: role in cardiovascular biology and disease. *Clin Sci* 2008;114:699-706.
15. Mattick JS, Makunin IV. Small regulatory RNAs in mammals. *Hum Mol Genet* 2005;14(Suppl 1): R121-R132.

16. Mattick JS, Makunin IV. Non-coding RNA. *Hum Mol Genet* 2006;15(Suppl 1):R17-R29.
17. Hastings ML, Krainer AR. Pre-mRNA splicing in the new millennium. *Curr Opin Cell Biol* 2001;13 (3):302-309.
18. Morey C, Avner P. Employment opportunities for non-coding RNAs. *FEBS Lett* 2004;567(1):27-34.
19. Bilen J, Nan L, Bonini NM. A new role for micro RNA pathways: modulation of degeneration induced by pathogenic human disease proteins. *Cell Cycle* 2006;5(24):2835-2838.
20. MicroRNA.org-
<http://www.microrna.org/microrna/searchMiRNAs.do>. Accessed on December 13, 2010.
21. Urbich C, Kuehnbacher A, Dimmeler S. Role of microRNAs in vascular diseases, inflammation, and angiogenesis. *Cardiovasc Res* 2008;79(4):581-588.
22. Baskerville S, Bartel DP. Microarray profiling of microRNAs reveals frequent co expression with neighboring miRNAs and host genes. *RNA* 2005; 11:241-247.
23. Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH, et al. MicroRNA genes are transcribed by RNA polymerase II. *EMBO J* 2004;23:4051-4060
24. Altuvia Y, Landgraf P, Lithwick G, Elefant N, Pfeffer S, Aravin A, et al. Clustering and conservation patterns of human microRNAs. *Nucl Acids Res* 2005;33(8):2697-2706.
25. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, et al. Microarray analysis shows that some microRNAs down-regulate large numbers of target mRNAs. *Nature* 2005;433:769-773.
26. Smalheiser NR, Torvik VI. Mammalian miRNAs derived from genomic repeats. *Trends Genet* 2005;21(6):322-326.
27. Whitelaw E, Martin DI. Retrotransposons as epigenetic mediators of phenotypic variation in mammals. *Nat Genet* 2001;27:361-365.
28. Peaston AE, Evsikov AV, Graber JH, de Vries WN, Holbrook AE, Solter D, et al. Retrotransposons regulate host genes in mouse oocytes and preimplantation embryos. *Dev Cell* 2004;7(4):597-606.
29. Devor EJ. Primate microRNAs miR-220 and miR-492 lie within processed pseudogenes. *J Hered* 2006;97(2):186-190.
30. Herbert A. The four Rs of RNA-directed evolutions. *Nat Genet* 2004;36:19-25. analysis of the human genome. *Nature* 2001;409:860-921.
31. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, et al. The sequence of the human genome. *Science* 2001;291(5507):1304-1351.
32. Szymanski M, Barciszewska MZ, Erdmann VA, Barciszewski J. A new frontier for molecular medicine: Noncoding RNAs. *Biochimica et Biophys Acta* 2005;1756(1):65-75.
33. Bartel D. MicroRNAs: genomics, biogenesis, mechanism, function. *Cell* 2004;116(2):281-297.
34. Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ. miRBase: tools for microRNA genomics. *Nucl Acids Res* 2008;36(Suppl 1):D154-D158.
35. AE Erson, EM Petty. MicroRNAs in development and disease. *Clin Genet* 2008;74(4): 296-306.
36. Aukerman MJ, Sakai H. Regulation of flowering time and floral organ identity by a microRNA and its APETALA2 like target genes. *Plant Cell* 2003; 15:2730-2741.
37. Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modulate hematopoietic lineage differentiation. *Science* 2004;303(5654):83-86.
38. Lagos-Quintana M, Rauhut R, Meyer J, Borkhardt A, Tuschl T. New microRNAs from mouse and human. *RNA* 2003;9:175-179.
39. Berezikov E, Plasterk RH. Camels and zebrafish, viruses and cancer: a microRNA update. *Hum Mol Genet* 2005;14(Suppl 2):R183-R190.
40. Bartel, B. MicroRNAs directing siRNA biogenesis. *Nat Struct Mol Biol* 2005;12(7):569-571.
41. Zamore PD, Haley B. Ribo-genome: the big world of small RNAs. *Science* 2005;309(5740):1519-1524.
42. Croce CM, Calin GA. miRNAs, cancer, and stem cell division. *Cell* 2005;122(1):6-7.
43. Klein ME, Impey S, Goodman RH. Role reversal: the regulation of neuronal gene expression by microRNAs. *Curr Opin Neurobiol* 2005;15(5): 507-513.
44. Giraldez AJ, Cinalli RM, Glasner ME, Enright AJ, Thomson JM, Baskerville S, et al. MicroRNAs regulate brain morphogenesis in zebrafish. *Science* 2005;308(5732):833-838.
45. Naguibneva I, Ameyar-Zazoua M, Poleskaya A, Ait-Si-Ali S, Groisman R, Souidi M, et al. The microRNA miR-181 targets the homeobox protein
46. Hatfield SD, Shcherbata HR, Fischer KA, Nakahara K, Carthew RW, Ruohola-Baker H. Stem cell division is regulated by the microRNA pathway. *Nature* 2005;435:974-978.
47. Mattick JS, Igor V. Makunin. Non-coding RNA. *Hum Mol Genet* 2006;15(Suppl 1):R17-R29.
48. McManus MT. MicroRNAs and cancer. *Semin Cancer Biol* 2003;13(4):253-258.
49. Bartel DP. MicroRNAs:genomics, biogenesis, mechanism and function. *Cell* 2004;116(2):281-297.
50. Szymanski M, Barciszewska MZ, Erdmann VA, Barciszewski J. A new frontier for molecular medicine: Noncoding RNAs. *Biochimica et Biophysica Acta* 2005;1756(1):65-75.
51. Soifer HS, Rossi JJ, Sætrom P. MicroRNAs in disease and potential therapeutic applications. *Mol Ther* 2007;15:2070-2079.
52. Li M, Mülle CM, Bharadwaj U, Chow KH, Yao Q, Chen C. MicroRNAs: control and loss of control in human physiology and disease. *World J Surg* 2009; 33(4):667-684.
53. Zhang B, Pan X, Cobb GP, Anderson TA. Micro RNAs

- as oncogenes and tumor suppressors. *Dev Biol* 2007;302(1):1-12.
54. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, et al. A microRNA component of the p53 tumor suppressor network. *Nature* 2007;447: 1130-1134.
 55. Suarez Y, Fernandez-Hernando C, Pober JS, Sessa WC. Dicer dependent microRNAs regulate gene expression and functions in human endothelial cells. *Circ Res* 2007;100:1164-1173.
 56. Kuehbacher A, Urbich C, Zeiher AM, Dimmeler S. Role of dicer and drosha for endothelial microRNA expression and angiogenesis. *Circ Res* 2007;101:59-68.
 57. Poliseno L, Tuccoli A, Mariani L, Evangelista M, Citti L, Woods K, et al. MicroRNAs modulate the angiogenic properties of HUVECs. *Blood* 2006;108(9):3068-3071.
 58. Chen Y, Gorski DH. Regulation of angiogenesis through a microRNA (miR-130a) that down-regulates antiangiogenic homeobox genes GAX and HOXA5. *Blood* 2008;111(3):1217-1226.
 59. Urbich C, Kuehbacher A, Dimmeler S. Role of microRNAs in vascular diseases, inflammation and angiogenesis. *Cardiovasc Res* 2008;79(4):581-588.
 60. Ziche M, Morbidelli L, Masini E, Amerini S, Granger HJ, Maggi CA, et al. Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. *J Clin Invest* 1994;94(5):2036-2044.
 61. Murohara T, Witzensbichler B, Spyridopoulos I, Asahara T, Ding B, Sullivan A, et al. Role of endothelial nitric oxide synthase in endothelial cell migration. *Arterioscler Thromb Vasc Biol* 1999;19:1156-1161.
 62. Rudic RD, Shesely EG, Maeda N, Smithies O, Segal SS, Sessa WC. Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling. *J Clin Invest* 1998;101(4):731-736.
 63. Murohara T, Asahara T, Silver M, Bauters C, Masuda H, Kalka C, et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. *J Clin Invest* 1998;101(11):2567-2578.
 64. Zeiher AM. Endothelial vasodilator dysfunction: pathogenetic link to myocardial ischaemia or epiphenomenon? *Lancet* 1996;348(Suppl 1):S10-S12.
 65. Aicher A, Heeschen C, Mildner-Rihm C, Urbich C, Ihling C, Technau-Ihling K, et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. *Nat Med* 2003;9:1370-1376.
 66. Iwakura A, Luedemann C, Shastri S, Hanley A, Kearney M, Aikawa R, et al. Estrogen-mediated, endothelial nitric oxide synthase-dependent mobilization of bone marrow-derived endothelial progenitor cells contributes to reendothelialization after arterial injury. *Circulation* 2003;108:3115-3121.
 67. Landmesser U, Engberding N, Bahlmann FH, Schaefer A, Wiencke A, Heineke A, et al. Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. *Circulation* 2004;110:1933-1939.
 68. Ikeda S, Kong SW, Lu J, Bisping E, Zhang H, Allen PD, et al. Altered microRNA expression in human heart disease. *Physiol Genomics* 2007;31:367-373.
 69. Zhao Y, Samal E, Srivastava D. Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. *Nature* 2005;436:214-220.
 70. Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A, et al. A mammalian microRNA expression atlas based on small RNA library sequencing. *Cell* 2007;129(7):1401-1414.
 71. Thum T, Catalucci D, Bauersachs J. MicroRNAs: novel regulators in cardiac development and disease. *Cardiovas Res* 2008;79:562-570.
 72. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. Identification of tissue-specific microRNAs from mouse. *Curr Biol* 2002;12(9):735-739.
 73. Chen JF, Mandel EM, Thomson JM, Wu Q, Callis TE, Hammond SM, et al. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. *Nat Genet* 2006;38:228-233.
 74. Van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J, Olson EN. Control of stress-dependent cardiac growth and gene expression by a micro RNA. *Science* 2007;316(5824):575-579.
 75. Zhao Y, Ransom JF, Li A, Vedantham V, von Drehle M, Muth AN, et al. Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. *Cell* 2007;129(2):303-317.
 76. Care A, Catalucci D, Felicetti F, Bonci D, Addario A, Gallo P, et al. MicroRNA-133 controls cardiac hypertrophy. *Nat Med* 2007;13:613-618.
 77. Yang B, Lin H, Xiao J, Lu Y, Luo X, Li B, et al. The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. *Nat Med* 2007;13:486-491.
 78. Catalucci D, Latronico MV, Ellingsen O, Condorelli G. Physiological myocardial hypertrophy: how and why? *Front Biosci* 2008; 13:312-324.
 79. Zhang C. MicroRNAs: role in cardiovascular biology and disease. *Clin Sci* 2008;114:699-706.
 80. Ross R. Atherosclerosis—an inflammatory disease. *N Engl J Med* 1999;340:115-126.
 81. Silvestre JS, Mallat Z, Tedgui A, Levy BI. Post-ischaemic neovascularization and inflammation. *Cardiovasc Res* 2008;78(2):242-249.
 82. Harris TA, Yamakuchi M, Ferlito M, Mendell JT, Lowenstein CJ. MicroRNA-126 regulates endothelial expression of vascular cell adhesion. *Proc Natl Acad Sci USA* 2008;105(5):1516-1521.
 83. O'Connell RM, Taganov KD, Boldin MP, Cheng G,

- Baltimore D. MicroRNA-155 is induced during the macrophage inflammatory response. *Proc Natl Acad Sci USA* 2007;104(5):1604-1609.
84. O'Connell RM, Rao DS, Chaudhuri AA, Boldin MP, Taganov KD, Nicoll J, et al. Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. *J Exp Med* 2008;205(3):585-594.
85. Rodriguez A, Vigorito E, Clare S, Warren MV, Couttet P, Soond DR, et al. Requirement of bic/microRNA-155 for normal immune function. *Science* 2007;316((5824):608-611.
86. Vigorito E, Perks KL, Abreu-Goodger C, Bunting S, Xiang Z, Kohlhaas S, et al. microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. *Immunity* 2007;27(6):847-859.
87. Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modulate hematopoietic lineage differentiation. *Science* 2004;303(5654):83-86.
88. Ventura A, Young AG, Winslow MM, Lintault L, Meissner A, Erkeland SJ, et al. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. *Cell* 2008;132:875-886.
89. Xiao C, Calado DP, Galler G, Thai TH, Patterson HC, Wang J, et al. MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb. *Cell* 2007;131(1):146-159.
90. Zhou B, Wang S, Mayr C, Bartel DP, Lodish HF. miR-150, a microRNA expressed in mature B and T cells, blocks early B cell development when expressed prematurely. *Proc Natl Acad Sci USA* 2007;104:7080-7085.
91. Rosa A, Ballarino M, Sorrentino A, Sthandier O, De Angelis FG, Marchioni M, et al. The interplay between the master transcription factor PU.1 and miR-424 regulates human monocyte/macrophage differentiation. *Proc Natl Acad Sci USA* 2007;104(50):19849-19854.
92. Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. *Proc Natl Acad Sci USA* 2006;103(33):12481-12486.
93. Johnnidis JB, Harris MH, Wheeler RT, Stehling-Sun S, Lam MH, Kirak O, et al. Regulation of progenitor cell proliferation and granulocyte function by microRNA-223. *Nature* 2008;451:1125-1129.
94. Beuvink I, Kolb FA, Budach W, Garnier A, Lange J, Natt F, et al. A novel microarray approach reveals new tissue-specific signatures of known and predicted mammalian microRNAs. *Nucl Acids Res* 2007;35(7):e52.
95. Sempere LF, Freemantle S, Pitha-Rowe I, Moss E, Dmitrovsky E, Ambros V. Expression profiling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with possible roles in murine and human neuronal differentiation. *Genome Biol* 2004;5:R13.
96. Berezikov E, Thummler F, van Laake LW, Kondova I, Bontrop R, Cuppen E, et al. Diversity of microRNAs in human and chimpanzee brain. *Nat Genet* 2006;38:1375-1377.
97. Miska EA, Alvarez-Saavedra E, Townsend M, Yoshii A, Sestan N, Rakic P, et al. Microarray analysis of microRNA expression in the developing mammalian brain. *Genome Biol* 2004;5:R68.
98. Nelson PT, Baldwin DA, Kloosterman WP, Kaupinen S, Plasterk RH, Mourelatos Z. RAKE and LNA-ISH reveal microRNA expression and localization in archival human brain. *RNA* 2006;12:187-191.
99. Singh SK. miRNAs: from neurogeneration to neurodegeneration. *Pharmacogenomics* 2007;8(8):971-978.
100. Smirnova L, Grafe A, Seiler A, Schumacher S, Nitsch R, Wulczyn FG. Regulation of miRNA expression during neural cell specification. *Eur J Neurosci* 2005;21(6):1469-1477.